...
首页> 外文期刊>Biotechnology Advances: An International Review Journal >Advances in pulmonary therapy and drug development: Lung tissue engineering to lung-on-a-chip
【24h】

Advances in pulmonary therapy and drug development: Lung tissue engineering to lung-on-a-chip

机译:肺部治疗和药物开发的进展:肺组织工程到单片肺

获取原文
获取原文并翻译 | 示例
           

摘要

Lung disease is one of the major causes of death, and the rate of pulmonary diseases has been increasing for decades. Although lung transplantation is the only treatment for majority of patients, this method has been limited due to lack of donors. Therefore, recently, attentions have increased to some new strategies with the aid of tissue engineering and microfluidics techniques not only for the functional analysis, but also for drug screening. In fact, in tissue engineering, the engineered tissue is able to grow by using the patient's own cells without intervention in the immune system. On the other hand, microfluidics devices are applied in order to evaluate drug screenings, function analysis and toxicity. This article reviews new advances in lung tissue engineering and lung-on-a-chip. Furthermore, future directions, difficulties and drawbacks of pulmonary therapy in these areas are discussed. (C) 2016 Elsevier Inc. All rights reserved.
机译:肺部疾病是主要的死亡原因之一,而且数十年来,肺部疾病的发病率一直在上升。尽管肺移植是大多数患者的唯一治疗方法,但由于缺乏供体,该方法受到了限制。因此,近来,借助组织工程和微流体技术,不仅对于功能分析,而且对于药物筛选,已经将注意力转向一些新策略。实际上,在组织工程中,工程组织可以通过使用患者自己的细胞生长而无需干预免疫系统。另一方面,应用微流体装置以评估药物筛选,功能分析和毒性。本文回顾了肺组织工程和片上肺的新进展。此外,讨论了这些领域中肺治疗的未来方向,困难和弊端。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号